In advanced Parkinson disease, motor fluctuations often extend beyond predictable wearing-off. Patients may report increasing “Off” time, shortened duration of benefit, troublesome dyskinesia, early morning akinesia, or nighttime rigidity despite optimized oral immediate-release levodopa. For some, variability spans the full 24-hour cycle and significantly affects sleep, function, and caregiver burden.
Continuous dopaminergic stimulation has been explored as one strategy to reduce the peaks and troughs associated with intermittent oral dosing. By providing more consistent levodopa exposure and minimizing pulsatile dopamine receptor activation, 24-hour continuous subcutaneous levodopa delivery aims to stabilize motor response throughout the day and night. Clinical trials have shown reductions in daily “Off” time and increases in “On” time compared with oral immediate-release regimens. Around-the-clock exposure may also help address early morning immobility and nocturnal motor symptoms that are not fully controlled by daytime dosing.
At the same time, fluctuations in advanced disease are multifactorial. Progressive loss of striatal buffering capacity, reduced long-duration response, and nonmotor symptom burden all contribute to variability. As a result, response to any advanced therapy can differ across patients.
Deciding when to move beyond oral therapy involves more than counting hours of “Off” time. Functional impairment, sleep fragmentation, fall risk, medication adherence challenges, and caregiver fatigue may all factor into escalation decisions. Patient selection for infusion-based therapy also requires consideration of practical issues, including device management, need for dose titration and ongoing monitoring, infusion-site reactions (eg, nodules, erythema, infection), and the patient’s or caregiver’s ability to manage a wearable pump system.
As treatment approaches evolve, 24-hour subcutaneous levodopa delivery represents one option within a broader management pathway that includes other device-aided and advanced interventions. Identifying the right patient—and the right timing—remains a nuanced clinical decision.
What clinical changes prompt you to consider continuous levodopa delivery? How do nocturnal symptoms influence your escalation strategy? What patient factors most shape your comfort with infusion-based management?
Share
-
Muhammad Nawaz13hOral therapy with Sinemet is always challenging give the tolerance with the GI side effect and becomes a barrier in efficacy and optimal clinical response So defnitely Infusion therapy is a welcome modailty for drug delivery and look forward to using it -
Joel Washinsky2dIf the patient is on a therapeutic dose of Sinemet and still having off periods, I'll try to place on continuous therapy.
-
Anjaneyulu Alapati6dwhen the pt is on high dose of sinemet and having off periods significantly. if the insurance approves can change to continuous
-
Temeki Hill1wwell first is patient's quality of life or lack thereof, and nocturnal symptoms play a role but overall symptom exacerbation really is the driving force to escalate therapy and as far as continuous infusion therapy, the ideal patient for this is a patient that previously has shown good/great compliance of their past care whether its for AD or other chronic conditions
-
ANDREW ROGOVE1wUsually if there are symptoms reported upon awakening or overnight, say when going to bathroom having difficulty ambulating, I will use continuous release CD-LD. As far as infusion based management it would depend on the patient and their ability to use the system or their support at home able to use system
-
Terry Cheung2wI usually talk to the patient and see if they're ready for the medication itself and look for their symptoms such as dyskinesia, EPS, motor functions or lack there of, pain, neuropathy, spasms, etc.
-
Terry Cheung2wI usually talk to the patient and see if they're ready for the medication itself and look for their symptoms such as dyskinesia, EPS, motor functions or lack there of, pain, neuropathy, spasms, etc.
-
SACHINKUMAR PANCHAL2wI consider continuous levodopa delivery when motor fluctuations, dyskinesias, or unpredictability persist despite optimized oral therapy, especially when nocturnal symptoms reveal round-the-clock dopaminergic gaps. The decision is ultimately shaped as much by patient readiness, support, and goals as by disease severity, since infusion therapies require meaningful engagement to succeed.